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Background: Ghrelin is known as a new endocrine component supposed to have an influence in control of
feeding behavior and energy balance. Recent studies have shown that ghrelin concentration in the subjects with
diabetes mellitus type 2 (DM 2) is lower than normal. To clarify the relationship between ghrelin and insulin
resistance and also DM 2, a cross-sectional study was designed.
Methods: In a cross-sectional study, 87 subjects were enrolled in three groups, 29 with DM2, 29 pre-diabetes state
and 29 normoglycemic subjects of first-degree relatives of diabetic group. After clinical examination, blood samples
were taken to measure fasting blood glucose, HbA1c, lipids, insulin, leptin and acylated ghrelin concentrations.
Results: Mean serum concentrations of acylated ghrelin in all groups (47.4 ± 27.9 pg/ml) were lower than normal
values (150.3 ± 56.4 pg/ml) (P: 0.006) without significant difference within groups comparison(P: 0.1). A significant
correlation was found between ghrelin concentration with body mass index (BMI) (r: -0.23, p <0.02) and abdominal
circumference (AC) (r: -0.28, P < 0.008). Also inverse relationship between ghrelin level and insulin resistance
(HOMA-IR) (r: -.032, p: 0.002) was seen in all subjects. Leptin level has a significant correlation with abdominal
circumference (AC) and BMI (P < 0.0001) but not with ghrelin.
Conclusion: This study showed that obesity has a strong association with the reduced level of ghrelin
concentration. It seems that the process of ghrelin reduction is initiated in earlier stages of insulin resistance prior
to the onset of overt DM.
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Diabetes mellitus (DM) is a heterogeneous disease that
is characterized by hyperglycemia and glucose intole-
rance [1,2]. Given the high prevalence of DM, identifying
the factors that may affect its process and cause the
pathological changes in the body is important [3]. Now-
adays a lot of changes in different hormones and cyto-
kines have been reported in DM that one of them is in a
hormone called ghrelin [3].* Correspondence: Mehdi.yamini.md@gmail.com
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reproduction in any medium, provided the orGhrelin is known as a new endocrine pathway in the
control of feeding behavior and energy balance in the
last decade. Ghrelin is a 28 amino acid hormone is
secreted by many tissues, but its main source is the gas-
tric mucosa [4-7]. Active form of ghrelin is acylated
ghrelin with some metabolic actions like stimulation the
appetite, increase the secretion of growth hormone, de-
crease insulin secretion from the pancreas, reducing in
energy consumption by the body and effects on growth
and peripheral metabolism especially of fats and carbo-
hydrates [8-11]. Ghrelin effects are mediated by growth
hormone receptor (GHS-R) in pancreatic islets cells,
hypothalamus - pituitary axis, kidney, small intestine
and placenta and stimulates growth hormone secretiontd. This is an open access article distributed under the terms of the Creative
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pancreas.
Reduction of electrical activity in β-cells is another pos-
sible mechanism of action for ghrelin. Low ghrelin levels
are associated with high levels of insulin and insulin resis-
tance [12]. On the other hand the plasma ghrelin levels
rise in malnutrition, cachexia and anorexia nervosa while
the levels are reduced in obesity. Lower ghrelin concentra-
tion in obesity have attributed to higher insulin concentra-
tion, also lower ghrelin levels after eating attributed to
increased insulin levels after carbohydrate intake in some
studies. It has been reported that injection of insulin in type
1 DM makes some reduction in ghrelin concentration.
Recent studies have shown that ghrelin concentration
in subjects with DM2 is lower than normal [3]. Some
studies supports the hypothesis that low ghrelin level
can be considered as a risk factor of diabetes mellitus
developing [12]. It's not clear whether low ghrelin level
is a risk factor for DM2 and initiates before developing
DM or is secondary to it [13].
Leptin is a hormone that works as a mediator in the
stomach – hypothalamus pathway and provides informa-
tion about the body's energy storage in adipocytes. Also,
its level is associated with obesity [3]. Leptin reduces the
amount of ghrelin secreted from the stomach. On the
other hand in an in vitro study on rat gastric mucosa,
leptin injections caused ghrelin suppression in over-
weight rats without any effect in normal- weight rats [3].
Whether low concentration of ghrelin is a primary or a
secondary event in DM2 is unclear and also its relation-
ship with leptin is ambiguous. So this study was designed
to describe acylated ghrelin and leptin concentrations in
people with different degrees of insulin resistance and dys-
glycemia including patients with new-onset DM2, people
with impaired fasting glucose (IFG)(prediabetes situation)
and those normoglycemic first-degree relatives of patients
with DM2. We also aimed to determine the relationship
between acylated ghrelin, leptin and insulin resistance in
the study groups.Methods
Subjects
This study was conducted on eighty-seven people who
were sequentially selected from those referred to Vali-asr
hospital, an academic hospital; in Zanjan, Iran in 2012.
Twenty-nine newly diagnosed DM2 subjects (one year
or less) were put into the first group. Twenty-nine with
fasting plasma glucose (FPG) concentration between 100
and 126 mg/dl confirmed twice in repeated measurements
or those with impaired glucose tolerance (IGT) defined by
ADA criteria (Two-hour plasma glucose 140–200 mg/dL
during a75 gr oral anhydrous glucose tolerance test )were
considered as prediabetes group 2.Offspring of patients with DM2 who were more than
twenty years old were invited and checked for their FPG
and those who were normoglycemic (FPG <100 mg/dl)
were entered in third group.
Who had history of using oral hypoglycemic agents or
insulin, medications that affect blood lipids or insulin
levels, supplements and appetite altering drugs, heart
failure, liver or renal failure and acute or chronic inflam-
matory disorders were excluded from the study.
This study was approved by ethical committee of Zanjan
University of Medical Sciences. All the participants were
informed about the aims of study and written consent
were obtained from all of them.
Measurements
Height, weight and waist circumference of the patients
were measured by standard methods and body mass index
(BMI) was calculated for all the participants. Blood pres-
sure was measured two times with a 15- minute interval
in sitting position and the mean of them was recorded for
each of the patients and pressures equal to or greater than
140/90 mm Hg on two occasions were considered as
hypertension. People with body mass index (BMI) higher
than 30 kg/m2 considered obese and those with BMI
between 25 to 30 kg/m2 were considered as overweight.
Abdominal obesity was defined as abdominal circum-
ference greater than 102 cm in men and 88 cm in women.
Waist to hip ratio (WHR) greater than 1 in men and 0.8
in women was considered high.
Blood samples were taken after at least 12 hours of
fasting in all the participants. Plasma glucose was mea-
sured by the glucose-peroxidase colorimetric enzymatic
method with a sensitivity of 5 mg/dl .Serum Cholesterol
and Triglyceride and High density lipoprotein cho-
lesterol (HDL-C) of all the participants were measured
enzymatically (Pars azmoon kit, Iran). Also HbA1c was
checked for all the participants using Nycocard method.
Fasting serum Insulin levels were measured with electro-
chemiluminescence immunoassay (ECLIA) using commer-
tial kits (Roche, German), with sensitivity of 0.75 μiu/ml
(normal range:0.7-25 μiu/ml). To calculate insulin resis-
tance, HOMA-IR was used based on the formula of
glucose × insulin/405 and values higher than 2.1 was con-
sidered insulin resistance [14].
To acquire accurate data on ghrelin concentrations, a
standard procedure for the collection of blood samples
was used including collection of blood samples with
EDTA–aprotinin ,keep them chilled and centrifuge as
soon as possible, within 30 min after the collection; and
acidification with 1 mol/L HCl (10% of sample volume)
added to the plasma sample for adjustment to pH 4 to
preserve plasma acylated ghrelin.
Plasma acylated-ghrelin and leptin were determined
using the Elisa kit from BioVendor Laboratory Medicine
Table 1 Comparison of clinical characteristics of people in three study groups
Clinical variables Group1: DM Group 2: pre-DM Group 3: p
N: 29 N: 29 Normoglycemic
N: 29
Age (years) 47.8 ± 11.6 53.5 ± 13.2 35.4 ± 9.2 0.00011
Weight (kg) 78.2 ± 18.2 73.7 ± 13.2 77.3 ± 14.1 0.521
BMI (kg/m2) 29.2 ± 5.4 27.8 ± 4.5 28.8 ± 4.3 0.548
WHR 0.88 ± 0.08 0.86 ± 0.06 0.83 ± 0.05 0.0091
AC (cm) 106.8 ± 13.5 102.7 ± 9.9 103.3 ± 11.2 0.365
SBP 129.6 ± 18.6 130 ± 17.3 120.1 ± 13.3 0.041
DBP 78.5 ± 11.5 76.4 ± 9.2 73.2 ± 9.2 0.138
Laboratory variable Mean ± SD median Mean ± SD median Mean ± SD median P
acylated ghrelin (pg/ml) 45.3 ± 33.2 40.1 45.5 ± 10.5 44.9 51.5 ± 40.2 56.5 0.1
Leptin (ng/ml) 15.2 ± 14 14.3 13.7 ± 10.5 13.2 16.2 ± 9.5 18.3 0.1
Insulin (μIU/ml) 5.5 ± 7.5 4.2 6.7 ± 5.3 5 6.8 ± 7.8 6.7 0.18
HOMA-IR 2.1 ± 2.5 2.3 1.7 ± 1.4 1.6 1.4 ± 1.6 1.5 0.4
Total Cholesterol (mg/dl) 188.3 ± 31.4 193 190 ± 45.6 196 172.8 ± 20.1 178 0.1
TG (mg/ dl) 190.9 ± 91.7 181 169 ± 82 174 104 ± 44.5 105 <0.0001
HDL (mg/ dl) 46.5 ± 6.4 45 43.3 ± 7.9 48 52.2 ± 3.9 56 <0.0001
LDL (mg/ dl) 103 ± 35.5 104 113.2 ± 38.7 113 99.7 ± 17.2 97 0.2
BMI: Body mass index, WHR: waist to hip ratio, AC: abdomen circumference, SBP: systolic blood pressure, DBP: diastolic blood pressure, TG: triglycerid.
CHOL: total cholestrole, LDL: low density lipoprotein.
Pvalue <0.05 is considered statistically significant.
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long immunological reaction method (incubation 4 to
20 hours) to achieve maximum sensitivity of 0.3 pg/ml
and 0.2 pg/ml for acylated ghrelin and leptin respec-
tively. Intra assay and inter assay CV of the kit to mea-
sure acylated ghrelin was 1.8% and 3.8% respectively.
Intra assay and inter assay CV of the leptin kit was 2.4%
and 5.4% respectively.
Statistical analysis
Data were analyzed with SPSS version 16.0 software. Des-
criptive statistics such as mean, median and standard de-
viation were used to describe the statistics. ANOVA was
used to compare the groups for quantitative and chi-Table 2 Comparison of the three studied groups for acylated
Acylated ghrelin Group1 Group 2
(DM) (pre-DM)
N:29 N:29
Normal BMI Overweight Obese Normal B
Mean 72.8 41.6 33.6 46.0
(pg/ml) ±62.3 ±20.3 ±7.3 ±15.1
Median 51.4 28.8 29.7 44.9
P 0.07 0.75
P value <0.05 is considered statistically significant.square test was used for qualitative variables. To assess
the relationship between the variables simple and multi-
variate regression analysis were used.
Results
87 eligible patients were assigned in 3 groups as follows:
29 subjects with diabetes mellitus type 2 in group one,
29 patients with IFG or IGT in group two, and 29 parti-
cipants with normoglycemic status in group three.
The mean age of the first group was 47.8 ± 11.6 years
and in the second group was 53.3 ± 13.2 years. Although
no significant difference was found between diabetic and
prediabetic patients for their age, normoglycemic subjects




MI Overweight Obese Normal BMI Overweight Obese
44.6 44.6 53.6 61.5 38.6
±12.7 ±24.2 ±6.1 ±58.4 ±10.3
40.9 37.8 56.8 48.6 39.7
0.04
Table 3 The relationship between acylated ghrelin levels with other variables in the three groups
Groups Variables DBP SBP insulin leptin FBS Waist AC WHR BMI
Group1 Acylated ghrelin r −0.21 −0.140 −0.402 −0.241 0.04 −0.464 −0.449 −0.151 −0.383
(DM)
N:29 p 0.25 0.43 0.03 0.20 0.81 0.01 0.01 0.43 0.04
Group 2 Acylated ghrelin r −0.06 −0.08 −0.205 −0.017 −0.150 −0.554 −0.314 −0.350 −0.181
(pre-DM)
N:29 p 0.73 0.63 0.28 0.93 0.43 0.002 0.09 0.06 0.34
Group 3 Acylated ghrelin r −0.034 −0.311 −0.201 −0.242 −0.099 −0.500 −0.434 −0.151 −0.572
(normoglycemic)
N:29 p −0.86 0.10 0.29 −0.20 0.61 0.02 0.01 0.42 0.03
BMI: Body mass index, WHR: waist to hip ratio, AC: abdomen circumference, SBP: systolic blood pressure, DBP: diastolic blood pressure, FBS: Fasting Blood Sugar.
Table 4 Result of multivariate regression analysis
acylated ghrelin with waist circumference (waist),
abdominal circumference (AC) and BMI and WHR after
removing the confounding factor of insulin,age and sex
AC BMI WHR Waist
Insulin is considered as
confounding factor
r −0.23 −0.07 −0.28 −0.28
Acylated ghrelin p 0.02 0.4 0.008 0.07
Age and sex are added as
confounding factors
Acylated ghrelin r -0.34 −0.31 -0.02 −0.11
P 0.001 0.003 0.8 0.08
BMI: Body mass index, WHR: waist to hip ratio, AC: abdomen circumference.
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three groups by sex. Clinical and laboratory characteristics
of the participants have been illustrated in Table 1.
Table 1 shows that clinical variables including weight,
BMI, abdominal circumference (AC) and diastolic blood
pressure was not statistically significant, while systolic
blood pressure in prediabetic group was significantly
higher than in normoglycemic subjects (P: 0.04) (group 3).
The prevalence of hypertension (HTN) in the diabetic
group (34.5%) was higher than the pre-diabetes group
(27.6%) and normal relatives (3.4%) (P: 0.004).
As illustrated in Table 1, triglyceride (TG ) concentra-
tion in the diabetic group was higher than two other
(p < 0.0001). Although HDL-c concentrations were lower
in diabetic and pre-diabetic subjects compared with nor-
mal individuals (p < 0.0001), the mean levels of LDL-c had
no significant differences among the three groups. The
prevalence of hypercholesterolemia in diabetic group was
significantly higher than the pre-diabetic and also normo-
glycemic subjects ( p: 0.008). Mean of serum insulin and
HOMA-IR was not statistically different among the three
groups (Table 1), but it was higher among obese subjects
(9.3 ± 9.1 pg/ml) rather than overweight (5.7 ± 5.1 pg/ml)
and normal BMI participants (3.4 ± 2.1 pg/ml) (p: 0.009).
Serum leptin was not statistically different within the three
groups (Table 1).
Acylated ghrelin concentrations in all three groups
(47.4 ± 27.9 pg/ml) were lower than normal values (199 ±
23 pg/ml) (P: 0.006). A serum concentration of acylated
ghrelin was not statistically different within groups’ com-
parison (p:0.1). Although no significant difference was
found between acylated ghrelin levels with obesity, over-
weight and normal BMI subjects in total subjects, acylated
ghrelin levels was lower in obese subjects of third group
(P: 0.04) (Table 2). On the other hand, no significant dif-
ference was observed between obese subjects in the three
groups for their mean of serum concentrations of acylated
ghrelin (P: 0.2). However, A significant inverse relationshipwas found between serum ghrelin concentration and ab-
dominal circumference (r: - 0.449, P: 0.01), BMI (r:- 0.383,
P: 0.04) and waist circumference (r: - 0.464, P: 0.01) in
diabetic group. Table 3 shows the relationship between
serum acylated ghrelin concentration and other variables
like obesity components in the three study groups. The
inverse relation of acylated ghrelin and BMI, abdominal or
waist circumference remain significant after adjusting
for other confounding factors in all the three groups
(Table 4).
There was an inverse relationship between acylated
ghrelin and insulin levels (r:- 0.402, P: 0.03) In the diabetic
group that was attenuated after adjusting for confounding
factors like age, sex, waist circumference and BMI (P: 0.5).
Also the inverse relationship between ghrelin and leptin
concentration which was found in all the study groups
was disappeared after adjusting age, sex, waist circum-
ference and BMI.
In all subjects, a direct relationship between leptin
levels with BMI and abdominal circumference was ob-
served (P: 0.001). The relationship between ghrelin, lep-
tin and insulin with other variables among three groups
are summarized in Table 5rnalRef>.
Table 5 The relationship between ghrelin, leptin and insulin, with all other variables in all subjects
DBP SBP HDL LDL CHOl TG HOMA -IR insulin ghrelin leptin FPG WC AC WHR BMI
Ghrelin r −0.1 −0.16 −0.12 −0.15 −0.08 −0.1 −0.32 −0.23 1 −0.1 −0.14 −0.51 −0.41 −0.2 −0.36
p 0.32 0.12 0.26 0.15 0.41 0.17 0.002 0.02 _ 0.19 0.19 0.001 0.001 0.06 0.001
Leptin r 0.26 0.22 0.17 0.19 0.24 0.03 0.19 −0.23 −0.1 1 −0.19 0.23 0.52 −0.3 0.6
p 0.01 0.03 0.1 0.07 0.02 0.72 0.06 0.02 0.19 _ 0.07 0.02 0.001 0.3 0.001
Insulin r −0.02 0.12 0.1 0.12 0.1 −0.01 0.95 1 −0.2 0.26 −0.92 0.39 0.25 0.15 0.32
p 0.85 0.26 0.35 0.26 0.33 0.87 0.0001 _ 0.02 0.01 0.39 0.001 0.01 0.16 0.002
BMI: Body mass index, TG: triglyceride, WHR: waist to hip ratio CHOL: total cholesterol, AC: abdominal circumference, LDL: low density lipoprotein, SBP: systolic
blood pressure, WC: Waist Circumference, HDL: high density lipoprotein.
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This study showed that acylated ghrelin levels in all the
subjects including patients with overt DM, subjects in
prediabetes stage and also first degree relatives of pa-
tients with diabetes who are normoglycemic, are lower
than the normal values. However, no significant dif-
ference was found between the three study groups for
their mean serum concentrations of acylated ghrelin. On
the other hand, acylated ghrelin concentration was more
related to body mass index and abdominal circumfe-
rence than hyperglycemia itself.
In Study of Monty et al. [15] an inverse relationship bet-
ween ghrelin levels, BMI and waist circumference was re-
ported that was in agreement of our study results. In our
study although a strong inverse correlation between mean
concentrations of ghrelin, mean levels of BMI and abdo-
minal circumference was found in all the groups when we
ranked subjects based on their BMI, no difference was
found between the obese ,overweight and normal weight
subjects for the ghrelin levels except for group 3. In
group3 obese individuals had lower ghrelin levels than
normal weight subjects, this issue also was observed in
diabetic patients with P: 0.07, which is close to significance
and appears to be significant in higher sample sizes.
Edrmann et al. [3] studied the effect of weight on ghrelin
levels and found that ghrelin levels were lower in obese
diabetics compared to normal obese individuals. They
attributed low levels of ghrelin in obese patients to the
effects of insulin, whereas in our study, after adjustment
for insulin effects as a confounding factor the inverse rela-
tionship between acylated ghrelin with overall and abdo-
minal obesity remained significant.
According to previous studies, ghrelin is one of the fac-
tors that are involved in appetite regulation [16,17] and
acts as an appetite stimulating factor to pass starvation
messages to brain. So its reduction in obesity can be con-
sidered as a defense mechanism of body to decrease appe-
tite. In fact, ghrelin is a natural antagonist of leptin [18]. It
seems that reduction in ghrelin in obesity is independent
of the influence on insulin.
Seppo et al. [13] in their study found that ghrelin levels
are inversely related to the blood glucose level and alsoreported lower ghrelin levels in patients with type 2 DM.
they exposed to discussion this question: Whether low
ghrelin levels in type 2 DM is primary or secondary to the
disease?
Our study showed that serum ghrelin concentrations
even in normoglycemic, insulin resistant people (group 3)
are significantly lower than normal ranges reported pre-
viously for general population. This issue probably shows
that the onset of decline in acylated ghrelin levels may be
prior to the onset of hyperglycemia. However, absence of
normal control group without insulin resistance in our
study may limit this conclusion.
Poyoko et al. [19], in their study found that there are an
inverse relationship between Ghrelin and IGF-1 levels
with insulin resistance in type 2 diabetes in middle-aged
subjects. We also obtained an inverse relationship bet-
ween acylated ghrelin levels with insulin resistance in all
subjects but after removing the effects of obesity, this
relationship did not remain significant. This issue may
propose a key role of obesity in ghrelin decline and insulin
resistance [20]. Furthermore, we found that the inverse re-
lationship between ghrelin and leptin concentrations is
due to obesity and after elimination the effect of obesity
there was no significant association between the two
mediators. This result also confirms the role of obesity as
a main factor to change the mediators like ghrelin and
leptin.
Seppo et al. [13] proposed low ghrelin level as a risk fac-
tor for hypertension, whereas in our study, no significant
correlation was found between systolic and diastolic blood
pressure and ghrelin concentration out of the effect of age
and BMI.
It seems that changes in some mediators secondary to
obesity as a main trigger leads to hyperglycemia that can
make changes in HDL-C and TG levels in blood.
Our study had some limitations; the first was low sam-
ple size in each group that was due to low access to sub-
jects who was eligible for the study. So any interpretation
should be made with caution. The second limitation was
absence of normal control group without risk factors like
relation to diabetic patients, to compare their serum acy-
lated ghrelin concentrations. We relied on normal ranges
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this may be misleading because of difference in genetic
and racial characteristics of the population.
Conclusions
The results of this study showed that ghrelin concentra-
tions decreases prior to the onset of hyperglycemia and are
more related to the fat pad of the body. Longitudinal stu-
dies with larger sample size would help to clarify aspects of
the subject.
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